Skip to content

Cardiogenomics Registry

CAD Genotype and Phenotype Cardiac Catheterization Laboratory Registry

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00861575
Acronym
CGR
Enrollment
2601
Registered
2009-03-13
Start date
2006-02-28
Completion date
2012-02-29
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

Cardiovascular

Brief summary

This is a continuous blood banking study that will archive plasma and blood permitting DNA and plasma analysis at a future date. Subjects are recruited at the time of a clinically required procedure and blood samples are collected and banked and used for future research. The main purpose of this study is to investigate the interaction of multiple phenotypes and genotypes and their impact on cardiovascular disease events and measures of atherosclerosis progression.

Interventions

None listed

Sponsors

Piedmont Healthcare
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* \> 17 years of age * Undergoing a clinical required cardiovascular procedure * Agree to donation of blood sample * Provide written informed consent and Authorization for Use/Disclosure of PHI

Exclusion criteria

* \< 18 years of age * Refusal to donate a blood sample * Refusal to provide written informed consent and Authorization for Use/Disclosure of PHI

Design outcomes

Primary

MeasureTime frame
To assess the relationship of multiple phenotypes and genotypes with cardiovascular diseaseYearly

Secondary

MeasureTime frame
To assess the impact of phenotypes and genotypes of specific patient subgroups (gender, ethnic, family history) on cardiovascular diseaseYearly

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026